Imperial College London
Alternate

ProfessorElaineHolmes

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Professor of Chemical Biology
 
 
 
//

Contact

 

+44 (0)20 7594 3220elaine.holmes

 
 
//

Location

 

661Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Alsaleh:2019:10.2147/HMER.S193996,
author = {Alsaleh, M and Barbera, TA and Reeves, HL and Cramp, M and Ryder, S and Gabra, H and Nash, K and Shen, Y-L and Holmes, E and Williams, R and Taylor-Robinson, SD},
doi = {10.2147/HMER.S193996},
journal = {Hepatic Medicine : Evidence and Research},
pages = {47--67},
title = {Characterisation of urinary metabolic profiles of cholangiocarcinoma in a United Kingdom population},
url = {http://dx.doi.org/10.2147/HMER.S193996},
volume = {11},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background Outside South-East Asia, most cases of cholangiocarcinoma have an obscure aetiology. There is often diagnostic uncertainty. Metabolomics using ultraperformance liquid chromatography mass spectrometry (UPLC-MS) offers the portent to distinguish disease-specific metabolic signatures.  We aimed to define such a urinary metabolic signature in a patient cohort with sporadic cholangiocarcinoma and investigate whether there were characteristic differences from those in patients with hepatocellular carcinoma, metastatic secondary liver cancer, pancreatic and ovarian cancer.Methods Spot urine specimens were obtained from 211 subjects in seven participating centres across the UK. Samples were collected from healthy controls and from patients with benign hepatic disease (gallstone, biliary strictures, sphincter of Oddi dysfunction and viral hepatitis) and patients with malignant conditions (hepatocellular carcinoma, pancreatic cancer, ovarian cancer and metastatic cancer in the liver). The spectral metabolite proles were generated using a UPLC-MS detector and data were analysed using multivariate and univariate statistical analyses.Results The greatest class differences were seen between the metabolic proles of disease-free controls compared to individuals with cholangiocarcinoma with altered acylcarnitine, bile acid and purine levels.  Individuals with benign strictures showed comparable urine proles to patients with malignant bile duct lesions. The metabolic signatures of patients with bile duct tumours were distinguishable from patients with hepatocellular and ovarian tumours, but no difference was observed between CCA cases and patients with pancreatic cancer or hepatic secondary metastases.Conclusion Cholangiocarcinoma causes subtle but detectable changes in the urine metabolic proles. The ndings point towards potential applications of metabonomics in early tumour detection. However, it is key to utilize both global and targeted metabonomics in a larger co
AU  - Alsaleh,M
AU  - Barbera,TA
AU  - Reeves,HL
AU  - Cramp,M
AU  - Ryder,S
AU  - Gabra,H
AU  - Nash,K
AU  - Shen,Y-L
AU  - Holmes,E
AU  - Williams,R
AU  - Taylor-Robinson,SD
DO  - 10.2147/HMER.S193996
EP  - 67
PY  - 2019///
SN  - 1179-1535
SP  - 47
TI  - Characterisation of urinary metabolic profiles of cholangiocarcinoma in a United Kingdom population
T2  - Hepatic Medicine : Evidence and Research
UR  - http://dx.doi.org/10.2147/HMER.S193996
UR  - http://hdl.handle.net/10044/1/68673
VL  - 11
ER  -
Download